# Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

> **NCT01246908** · PHASE2 · COMPLETED · sponsor: **CeNeRx BioPharma Inc.** · enrollment: 360 (actual)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** Placebo
- **DRUG:** CX157 (TriRima)

## Key facts

- **NCT ID:** NCT01246908
- **Lead sponsor:** CeNeRx BioPharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2012-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01246908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01246908, "Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01246908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*